Researchers have identified a previously unknown mechanism by which the kidney precisely controls calcium excretion. The ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered risk for kidney outcomes consistently across BMI subgroups in the FLOW trial. Body weight ...
Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and chronic kidney disease have a 24% lower risk for kidney disease progression and ...
Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in ...
OAK BROOK, Ill. - Blood flow changes in the brains of children, adolescents and young adults with chronic kidney disease may explain why many face a higher risk of cognitive impairment, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results